Kiora Pharmaceuticals Inc... (KPRX)
Kiora Pharmaceuticals Statistics
Share Statistics
Kiora Pharmaceuticals has 3M shares outstanding. The number of shares has increased by 1.02% in one year.
Shares Outstanding | 3M |
Shares Change (YoY) | 1.02% |
Shares Change (QoQ) | 0% |
Owned by Institutions (%) | 1.12% |
Shares Floating | 2.8M |
Failed to Deliver (FTD) Shares | 433 |
FTD / Avg. Volume | 1.37% |
Short Selling Information
The latest short interest is 3.61K, so 0.12% of the outstanding shares have been sold short.
Short Interest | 3.61K |
Short % of Shares Out | 0.12% |
Short % of Float | 0.13% |
Short Ratio (days to cover) | 0.27 |
Valuation Ratios
The PE ratio is 3.56 and the forward PE ratio is -1.54. Kiora Pharmaceuticals's PEG ratio is -0.03.
PE Ratio | 3.56 |
Forward PE | -1.54 |
PS Ratio | 0.8 |
Forward PS | 0.4 |
PB Ratio | 0.5 |
P/FCF Ratio | 1.49 |
PEG Ratio | -0.03 |
Enterprise Valuation
Kiora Pharmaceuticals has an Enterprise Value (EV) of 9.04M.
EV / Sales | 0.56 |
EV / EBITDA | 1.59 |
EV / EBIT | 1.06 |
EV / FCF | 1.06 |
Financial Position
The company has a current ratio of 4.94, with a Debt / Equity ratio of 0.
Current Ratio | 4.94 |
Quick Ratio | 4.94 |
Debt / Equity | 0 |
Debt / EBITDA | 0.01 |
Debt / FCF | 0.01 |
Interest Coverage | 210.31 |
Financial Efficiency
Return on Equity is 13.95% and Return on Invested Capital is 9.39%.
Return on Equity | 13.95% |
Return on Assets | 9.85% |
Return on Invested Capital | 9.39% |
Revenue Per Employee | $1.33M |
Profits Per Employee | $299.56K |
Employee Count | 12 |
Asset Turnover | 0.44 |
Inventory Turnover | n/a |
Taxes
Income Tax | 2.07M |
Effective Tax Rate | 36.49% |
Stock Price Statistics
The stock price has increased by -48.03% in the last 52 weeks. The beta is -0.46, so Kiora Pharmaceuticals's price volatility has been lower than the market average.
Beta | -0.46 |
52-Week Price Change | -48.03% |
50-Day Moving Average | 3.41 |
200-Day Moving Average | 3.63 |
Relative Strength Index (RSI) | 33.13 |
Average Volume (20 Days) | 31.53K |
Income Statement
In the last 12 months, Kiora Pharmaceuticals had revenue of 16.02M and earned 3.59M in profits. Earnings per share was 1.99.
Revenue | 16.02M |
Gross Profit | 16.02M |
Operating Income | 4.51M |
Net Income | 3.59M |
EBITDA | 5.7M |
EBIT | 5.68M |
Earnings Per Share (EPS) | 1.99 |
Balance Sheet
The company has 3.79M in cash and 57.17K in debt, giving a net cash position of 3.74M.
Cash & Cash Equivalents | 3.79M |
Total Debt | 57.17K |
Net Cash | 3.74M |
Retained Earnings | -143.38M |
Total Assets | 36.48M |
Working Capital | 23.7M |
Cash Flow
In the last 12 months, operating cash flow was 8.56M and capital expenditures -6.26K, giving a free cash flow of 8.55M.
Operating Cash Flow | 8.56M |
Capital Expenditures | -6.26K |
Free Cash Flow | 8.55M |
FCF Per Share | 2.21 |
Margins
Gross margin is 100%, with operating and profit margins of 28.15% and 22.44%.
Gross Margin | 100% |
Operating Margin | 28.15% |
Pretax Margin | 35.33% |
Profit Margin | 22.44% |
EBITDA Margin | 35.58% |
EBIT Margin | 28.15% |
FCF Margin | 53.39% |
Dividends & Yields
KPRX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | 28.13% |
FCF Yield | 66.93% |
Analyst Forecast
The average price target for KPRX is $10, which is 261% higher than the current price. The consensus rating is "Buy".
Price Target | $10 |
Price Target Difference | 261% |
Analyst Consensus | Buy |
Analyst Count | 1 |
Stock Splits
The last stock split was on Jun 11, 2024. It was a backward split with a ratio of 1:9.
Last Split Date | Jun 11, 2024 |
Split Type | backward |
Split Ratio | 1:9 |
Scores
Altman Z-Score | -3.25 |
Piotroski F-Score | 7 |